Skip to main content
MedPath Trial logoMedPath TrialMedPath Trial Home
Clinical Trials/NCT00387140
NCT00387140CompletedPhase 2

A Randomized Double-blind, Placebo-and Active Comparator-Controlled 2-Part Study to Evaluate the Efficacy of MK2295 in Patients With Postoperative Dental Pain

Merck Sharp & Dohme LLC0 sites89 target enrollmentStarted: October 2006Last updated:
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit
Conditions
Drugs

Trial Snapshot

Phase
Phase 2
Status
Completed
Enrollment
89
Primary Endpoint
Peak analgesic response, safety, and tolerability
Study OverviewStudy DesignEligibility CriteriaOutcomesInvestigatorsRecords & IdentifiersSimilar Trials

Study Overview

Brief Summary

This study is being conducted to evaluate the safety and tolerability of the drug and to evaluate its efficacy compared to placebo and to ibuprofen in the treatment of postoperative dental pain in male patients.

Study Design

Study Type
Interventional
Allocation
Randomized
Intervention Model
Parallel
Primary Purpose
Treatment
Masking
Double (Participant, Investigator)

Eligibility Criteria

Ages
18 Years to 45 Years (Adult)
Sex
Male
Accepts Healthy Volunteers
Yes

Inclusion Criteria

  • •Patients in generally good health who are scheduled to have two or more third molars removed, at least one of which is partially or completely embedded in bone and is a mandibular impaction

Exclusion Criteria

  • •Patient has a temperature of 37.5C or greater prior to dosing
  • •Patient has participated in another clinical study within the last 4 weeks

Outcomes

Primary Outcomes

Peak analgesic response, safety, and tolerability

Time Frame: Over 24 Hours

Secondary Outcomes

  • Onset of analgesia, duration of analgesia(Over 24 Hours)

Investigators

Sponsor Class
Industry
Responsible Party
Sponsor

Similar Trials

Completed
Phase 1
Single and Multiple Ascending Oral Dose Study of RX-10001 in Healthy VolunteersHealthy
NCT00941018Resolvyx Pharmaceuticals, Inc56
Completed
Phase 1
An Evaluation of VR942 in Healthy Volunteers and Patients With Mild AsthmaAsthma
NCT02473939Vectura Limited85
Unknown
Phase 1
Tolerability, Safety and Pharmacokinetic Study Of Mianhuahua Flavonoids Tablets in Healthy Adult SubjectsHealthy
NCT02622230Xinjiang Uygur Pharmaceutical Co., Ltd.60
Completed
Phase 1
A Study to Evaluate LY3202328 in Overweight Healthy Participants and DyslipidemiaDyslipidemias
NCT02714569Eli Lilly and Company60
Terminated
Phase 1
Multiple Ascending Dose Study in Subjects With Type 2 DiabetesDiabetes Mellitus
NCT01856881Amgen86
A Study to Evaluate the Safety and... | Clinical Trial